218 related articles for article (PubMed ID: 32710396)
1. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
[TBL] [Abstract][Full Text] [Related]
2. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
Bass AD; Arroyo R; Boster AL; Boyko AN; Eichau S; Ionete C; Limmroth V; Navas C; Pelletier D; Pozzilli C; Ravenscroft J; Sousa L; Tintoré M; Uitdehaag BMJ; Baker DP; Daizadeh N; Choudhry Z; Rog D;
Mult Scler Relat Disord; 2021 Apr; 49():102717. PubMed ID: 33476880
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
Okai AF; Amezcua L; Berkovich RR; Chinea AR; Edwards KR; Steingo B; Walker A; Jacobs AK; Daizadeh N; Williams MJ;
Neurol Ther; 2019 Dec; 8(2):367-381. PubMed ID: 31654272
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
6. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Arroyo R; Bury DP; Guo JD; Margolin DH; Melanson M; Daizadeh N; Cella D
Mult Scler; 2020 Jul; 26(8):955-963. PubMed ID: 31144568
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Coles AJ; Achiron A; Traboulsee A; Singer BA; Pozzilli C; Oreja-Guevara C; Giovannoni G; Comi G; Freedman MS; Ziemssen T; Shiota D; Rawlings AM; Wong AT; Chirieac M; Montalban X
Ther Adv Neurol Disord; 2023; 16():17562864231194823. PubMed ID: 37745914
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Steingo B; Al Malik Y; Bass AD; Berkovich R; Carraro M; Fernández Ó; Ionete C; Massacesi L; Meuth SG; Mitsikostas DD; Pardo G; Simm RF; Traboulsee A; Choudhry Z; Daizadeh N; Compston DAS;
J Neurol; 2020 Nov; 267(11):3343-3353. PubMed ID: 32583052
[TBL] [Abstract][Full Text] [Related]
10. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Kuhle J; Daizadeh N; Benkert P; Maceski A; Barro C; Michalak Z; Sormani MP; Godin J; Shankara S; Samad TA; Jacobs A; Chung L; Rӧsch N; Kaiser C; Mitchell CP; Leppert D; Havari E; Kappos L
Mult Scler; 2022 Apr; 28(4):573-582. PubMed ID: 34378446
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
Havrdova E; Arnold DL; Cohen JA; Hartung HP; Fox EJ; Giovannoni G; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Rodriguez CE; Jody D; Hogan RJ; Xenopoulos P; Panzara MA; Coles AJ;
Neurology; 2017 Sep; 89(11):1107-1116. PubMed ID: 28835401
[TBL] [Abstract][Full Text] [Related]
14. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Coles AJ; Arnold DL; Bass AD; Boster AL; Compston DAS; Fernández Ó; Havrdová EK; Nakamura K; Traboulsee A; Ziemssen T; Jacobs A; Margolin DH; Huang X; Daizadeh N; Chirieac MC; Selmaj KW
Ther Adv Neurol Disord; 2021; 14():1756286420982134. PubMed ID: 34035833
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Comi G; Alroughani R; Boster AL; Bass AD; Berkovich R; Fernández Ó; Kim HJ; Limmroth V; Lycke J; Macdonell RA; Sharrack B; Singer BA; Vermersch P; Wiendl H; Ziemssen T; Jacobs A; Daizadeh N; Rodriguez CE; Traboulsee A;
Mult Scler; 2020 Dec; 26(14):1866-1876. PubMed ID: 31762387
[TBL] [Abstract][Full Text] [Related]
17. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
